A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
Status:
Unknown status
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
This study is a pilot trial evaluating the safety and immunogenicity of AADvac1 in patients
with the non-fluent variant of Primary Progressive Aphasia.
50% of participants will receive the 40 µg dosage of AADvac1 and 50% of participants will
receive the 160 µg dosage of AADvac1. No placebo is used.